TA
BMRN icon

Tiedemann Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tiedemann Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,829
Closed -$226K – 318
2020
Q2 		$226K Buy
+1,829
New +$182K 0.01% 268

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tiedemann Advisors's BMRN Position: Q3 2020 in Review

Tiedemann Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 1,829 shares — an estimated $226K sold.

Tiedemann Advisors first reported a position in BMRN in Q2 2020 and held it in 1 quarter. The position peaked at $226K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • Tiedemann Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Tiedemann Advisors sold 1,829 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $226K.
  • Tiedemann Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Tiedemann Advisors's BioMarin Pharmaceuticals position peaked at $226K in Q2 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Tiedemann Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.